N-ras gene mutations in childhood acute non-lymphoblastic leukemia

Naohiro Terada, Thomas J. Smith, Linda Stork, Lorrie F. Odom, Erwin W. Gelfand

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In view of the potential role for ras activation in leukemogenesis, we have screened a number of children with acute non-lymphoblastic leukemia (ANLL) for activating point mutations at codons 12, 13 and 61 of the N-ras proto-oncogene using panels of oligonucleotide probes in conjunction with polymerase chain reaction (PCR) gene amplification. In contrast to the frequent occurrence (∼ 30%) of N-ras mutation reported in adult ANLL, 6 of 46 cases (13%) at the time of diagnosis had N-ras mutations involving codons 12 and 13. In these patients we also determine whether presenting clinical symptoms, cellular pathology, karyotype, or eventual outcome distinguished them from the ras-negative group. N-ras activation tended to be associated with a higher white blood cell count at diagnosis (mean of 225 000/μl vs 91 000/μl) and fewer remissions obtained after 28 days of therapy ( 3 6, 50% vs 24 32, 75%). It is possible that activation of N-ras oncogene may be involved in the progression of some cases of childhood ANLL.

Original languageEnglish (US)
Pages (from-to)935-941
Number of pages7
JournalLeukemia Research
Volume15
Issue number10
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

ras Genes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Codon
Mutation
Proto-Oncogenes
Oligonucleotide Probes
Gene Amplification
Karyotype
Leukocyte Count
Point Mutation
Pathology
Polymerase Chain Reaction
Therapeutics

Keywords

  • childhood ANLL
  • N-ras activation

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

N-ras gene mutations in childhood acute non-lymphoblastic leukemia. / Terada, Naohiro; Smith, Thomas J.; Stork, Linda; Odom, Lorrie F.; Gelfand, Erwin W.

In: Leukemia Research, Vol. 15, No. 10, 1991, p. 935-941.

Research output: Contribution to journalArticle

Terada, Naohiro ; Smith, Thomas J. ; Stork, Linda ; Odom, Lorrie F. ; Gelfand, Erwin W. / N-ras gene mutations in childhood acute non-lymphoblastic leukemia. In: Leukemia Research. 1991 ; Vol. 15, No. 10. pp. 935-941.
@article{b3d50e327af54628892f69a613c76911,
title = "N-ras gene mutations in childhood acute non-lymphoblastic leukemia",
abstract = "In view of the potential role for ras activation in leukemogenesis, we have screened a number of children with acute non-lymphoblastic leukemia (ANLL) for activating point mutations at codons 12, 13 and 61 of the N-ras proto-oncogene using panels of oligonucleotide probes in conjunction with polymerase chain reaction (PCR) gene amplification. In contrast to the frequent occurrence (∼ 30{\%}) of N-ras mutation reported in adult ANLL, 6 of 46 cases (13{\%}) at the time of diagnosis had N-ras mutations involving codons 12 and 13. In these patients we also determine whether presenting clinical symptoms, cellular pathology, karyotype, or eventual outcome distinguished them from the ras-negative group. N-ras activation tended to be associated with a higher white blood cell count at diagnosis (mean of 225 000/μl vs 91 000/μl) and fewer remissions obtained after 28 days of therapy ( 3 6, 50{\%} vs 24 32, 75{\%}). It is possible that activation of N-ras oncogene may be involved in the progression of some cases of childhood ANLL.",
keywords = "childhood ANLL, N-ras activation",
author = "Naohiro Terada and Smith, {Thomas J.} and Linda Stork and Odom, {Lorrie F.} and Gelfand, {Erwin W.}",
year = "1991",
doi = "10.1016/0145-2126(91)90170-X",
language = "English (US)",
volume = "15",
pages = "935--941",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - N-ras gene mutations in childhood acute non-lymphoblastic leukemia

AU - Terada, Naohiro

AU - Smith, Thomas J.

AU - Stork, Linda

AU - Odom, Lorrie F.

AU - Gelfand, Erwin W.

PY - 1991

Y1 - 1991

N2 - In view of the potential role for ras activation in leukemogenesis, we have screened a number of children with acute non-lymphoblastic leukemia (ANLL) for activating point mutations at codons 12, 13 and 61 of the N-ras proto-oncogene using panels of oligonucleotide probes in conjunction with polymerase chain reaction (PCR) gene amplification. In contrast to the frequent occurrence (∼ 30%) of N-ras mutation reported in adult ANLL, 6 of 46 cases (13%) at the time of diagnosis had N-ras mutations involving codons 12 and 13. In these patients we also determine whether presenting clinical symptoms, cellular pathology, karyotype, or eventual outcome distinguished them from the ras-negative group. N-ras activation tended to be associated with a higher white blood cell count at diagnosis (mean of 225 000/μl vs 91 000/μl) and fewer remissions obtained after 28 days of therapy ( 3 6, 50% vs 24 32, 75%). It is possible that activation of N-ras oncogene may be involved in the progression of some cases of childhood ANLL.

AB - In view of the potential role for ras activation in leukemogenesis, we have screened a number of children with acute non-lymphoblastic leukemia (ANLL) for activating point mutations at codons 12, 13 and 61 of the N-ras proto-oncogene using panels of oligonucleotide probes in conjunction with polymerase chain reaction (PCR) gene amplification. In contrast to the frequent occurrence (∼ 30%) of N-ras mutation reported in adult ANLL, 6 of 46 cases (13%) at the time of diagnosis had N-ras mutations involving codons 12 and 13. In these patients we also determine whether presenting clinical symptoms, cellular pathology, karyotype, or eventual outcome distinguished them from the ras-negative group. N-ras activation tended to be associated with a higher white blood cell count at diagnosis (mean of 225 000/μl vs 91 000/μl) and fewer remissions obtained after 28 days of therapy ( 3 6, 50% vs 24 32, 75%). It is possible that activation of N-ras oncogene may be involved in the progression of some cases of childhood ANLL.

KW - childhood ANLL

KW - N-ras activation

UR - http://www.scopus.com/inward/record.url?scp=0026050947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026050947&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(91)90170-X

DO - 10.1016/0145-2126(91)90170-X

M3 - Article

VL - 15

SP - 935

EP - 941

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 10

ER -